Search

Control of serum phosphorus remains a vexing problem in chronic kidney disease. Although novel dialysis regimens may provide excellent phosphorus control, phosphate binders remain necessary for most dialysis patients. Block et al. present a phase I clinical trial examining the safety and efficacy of SBR759, a novel non-calcium, iron-based phosphate binder. Although the risks of iron accumulation and hypocalcemia must be addressed, this phosphate binder appears to be well tolerated and effective and offers a powder-based formulation. [ABSTRACT FROM AUTHOR]

A letter to the editor is presented in response to the article "Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease," by D. R. Ashby and colleagues.